Protection of Farm Goats by Combinations of Recombinant Peptides and Formalin Inactivated Spores from a Lethal Bacillus Anthracis Challenge Under Field Conditions

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2017 Jul 14

PMID 28701192

Citations 3

Authors

Susanne M Koehler

Fatih Buyuk

Ozgur Celebi

Hayati Demiraslan

Mehmet Doganay

Mitat Sahin

Jens Moehring

Okechukwu C Ndumnego

Salih Otlu

Henriette van Heerden

Wolfgang Beyer

Affiliations

Soon will be listed here.

Abstract

Background: Bacillus (B.) anthracis, the causal agent of anthrax, is effectively controlled by the Sterne live spore vaccine (34F2) in animals. However, live spore vaccines are not suitable for simultaneous vaccination and antibiotic treatment of animals being at risk of infection in an outbreak situation. Non-living vaccines could close this gap.

Results: In this study a combination of recombinant protective antigen and recombinant Bacillus collagen-like antigen (rBclA) with or without formalin inactivated spores (FIS), targeted at raising an immune response against both the toxins and the spore of B. anthracis, was tested for immunogenicity and protectiveness in goats. Two groups of goats received from local farmers of the Kars region of Turkey were immunized thrice in three weeks intervals and challenged together with non-vaccinated controls with virulent B. anthracis, four weeks after last immunization. In spite of low or none measurable toxin neutralizing antibodies and a surprisingly low immune response to the rBclA, 80% of the goats receiving the complete vaccine were protected against a lethal challenge. Moreover, the course of antibody responses indicates that a two-step vaccination schedule could be sufficient for protection.

Conclusion: The combination of recombinant protein antigens and FIS induces a protective immune response in goats. The non-living nature of this vaccine would allow for a concomitant antibiotic treatment and vaccination procedure. Further studies should clarify how this vaccine candidate performs in a post infection scenario controlled by antibiotics.

Citing Articles

Immunogenicity and Protective Efficacy of a Non-Living Anthrax Vaccine versus a Live Spore Vaccine with Simultaneous Penicillin-G Treatment in Cattle.

Jauro S, Ndumnego O, Ellis C, Buys A, Beyer W, van Heerden H Vaccines (Basel). 2020; 8(4).

PMID: 33050254 PMC: 7711464. DOI: 10.3390/vaccines8040595.

Immunogenicity of Non-Living Anthrax Vaccine Candidates in Cattle and Protective Efficacy of Immune Sera in A/J Mouse Model Compared to the Sterne Live Spore Vaccine.

Jauro S, Ndumnego O, Ellis C, Buys A, Beyer W, van Heerden H Pathogens. 2020; 9(7).

PMID: 32664259 PMC: 7400155. DOI: 10.3390/pathogens9070557.

Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model.

Ndumnego O, Koehler S, Crafford J, Beyer W, van Heerden H Sci Rep. 2018; 8(1):16937.

PMID: 30446695 PMC: 6240085. DOI: 10.1038/s41598-018-35382-8.

References

Hahn U, Boehm R, Beyer W . DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine. 2005; 24(21):4569-71. DOI: 10.1016/j.vaccine.2005.08.031. View

Basu S, Kang T, Chen W, Fenton M, Baillie L, Hibbs S . Role of Bacillus anthracis spore structures in macrophage cytokine responses. Infect Immun. 2007; 75(5):2351-8. PMC: 1865778. DOI: 10.1128/IAI.01982-06. View

Steichen C, Kearney J, Turnbough Jr C . Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J Bacteriol. 2005; 187(17):5868-76. PMC: 1196169. DOI: 10.1128/JB.187.17.5868-5876.2005. View

Brossier F, Mock M, Sirard J . Role of toxin functional domains in anthrax pathogenesis. Infect Immun. 2000; 68(4):1781-6. PMC: 97348. DOI: 10.1128/IAI.68.4.1781-1786.2000. View

Brossier F, Levy M, Mock M . Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun. 2002; 70(2):661-4. PMC: 127709. DOI: 10.1128/IAI.70.2.661-664.2002. View

Ivins B, Pitt M, Fellows P, Farchaus J, Benner G, Waag D . Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998; 16(11-12):1141-8. DOI: 10.1016/s0264-410x(98)80112-6. View

Turnbull P, Broster M, Carman J, Manchee R, Melling J . Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun. 1986; 52(2):356-63. PMC: 261006. DOI: 10.1128/iai.52.2.356-363.1986. View

Rhie G, Roehrl M, Mourez M, Collier R, Mekalanos J, Wang J . A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci U S A. 2003; 100(19):10925-30. PMC: 196904. DOI: 10.1073/pnas.1834478100. View

Loleit M, Ihlenfeldt H, Brunjes J, Jung G, Muller B, Hoffmann P . Synthetic peptides coupled to the lipotripeptide P3CSS induce in vivo B and Thelper cell responses to HIV-1 reverse transcriptase. Immunobiology. 1996; 195(1):61-76. DOI: 10.1016/s0171-2985(96)80006-4. View

10.

Little S, Knudson G . Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun. 1986; 52(2):509-12. PMC: 261029. DOI: 10.1128/iai.52.2.509-512.1986. View

11.

Enkhtuya J, Kawamoto K, Kobayashi Y, Uchida I, Rana N, Makino S . Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology (Reading). 2006; 152(Pt 10):3103-3110. DOI: 10.1099/mic.0.28788-0. View

12.

Stepanov A, Marinin L, Pomerantsev A, Staritsin N . Development of novel vaccines against anthrax in man. J Biotechnol. 1996; 44(1-3):155-60. DOI: 10.1016/0168-1656(95)00092-5. View

13.

Kohler S, Baillie L, Beyer W . BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge. Vaccine. 2015; 33(24):2771-7. DOI: 10.1016/j.vaccine.2015.04.049. View

14.

Ivins B, Welkos S, Little S, Crumrine M, Nelson G . Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun. 1992; 60(2):662-8. PMC: 257681. DOI: 10.1128/iai.60.2.662-668.1992. View

15.

Jackson F, Wright G, Armstrong J . Immunization of cattle against experimental anthrax with alum-precipitated protective antigen or spore vaccine. Am J Vet Res. 1957; 18(69):771-7. View

16.

Ivins B, Welkos S . Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol. 1988; 4(1):12-9. DOI: 10.1007/BF00152686. View

17.

Wiesmuller K, Jung G, Hess G . Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine. 1989; 7(1):29-33. DOI: 10.1016/0264-410x(89)90007-8. View

18.

Glomski I, Corre J, Mock M, Goossens P . Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol. 2007; 178(5):2646-50. DOI: 10.4049/jimmunol.178.5.2646. View

19.

Baillie L . Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol. 2006; 101(3):594-606. DOI: 10.1111/j.1365-2672.2006.03112.x. View

20.

Wang Y, Jenkins S, Gu C, Shree A, Martinez-Moczygemba M, Herold J . Bacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore Persistence. PLoS Pathog. 2016; 12(6):e1005678. PMC: 4909234. DOI: 10.1371/journal.ppat.1005678. View